Haleon plc Reports Share Transaction
Ticker: HLNCF · Form: 6-K · Filed: Sep 20, 2024 · CIK: 1900304
Sentiment: neutral
Topics: share-buyback, company-update
TL;DR
Haleon bought back some of its own stock on 9/20.
AI Summary
Haleon plc announced on September 20, 2024, that it conducted a transaction in its own shares. The filing does not specify the number of shares or the financial details of this transaction.
Why It Matters
This filing indicates activity related to Haleon's share capital, which could signal management's view on the company's valuation or capital allocation strategy.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of share transactions and does not contain significant new financial or operational information.
Key Players & Entities
- Haleon plc (company) — Registrant
- DRVW 2022 Ltd (company) — Former name of Haleon plc
- September 20, 2024 (date) — Date of share transaction announcement
FAQ
What specific transaction in own shares did Haleon plc conduct?
Haleon plc announced a 'Transaction in Own Shares' on September 20, 2024, as detailed in Exhibit 99.1.
When was this transaction in own shares announced?
The transaction was announced on September 20, 2024.
Does this filing provide details on the number of shares or the value of the transaction?
The provided text of the 6-K filing does not specify the number of shares or the financial value of the transaction in its own shares.
What is Haleon plc's former name?
Haleon plc's former name was DRVW 2022 Ltd, with a date of name change on December 17, 2021.
Under which SEC form does Haleon plc typically file its annual reports?
Haleon plc indicates it files annual reports under cover of Form 20-F.
Filing Stats: 544 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-09-20 13:41:24
Filing Documents
- haleonplc-1278f.htm (6-K) — 31KB
- 0001654954-24-012140.txt ( ) — 32KB
From the Filing
IN OWN SHARES haleonplc-1278f   UNITED STATES   SECURITIES AND EXCHANGE COMMISSION   Washington, D.C. 20549     FORM 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934   For the month of September 2024   Commission File Number: 001-41411   Haleon plc (Translation of registrant’s name into English)   Building 5, First Floor, The Heights, Weybridge, Surrey, KT13 0NY (Address of principal executive offices)     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:     Form 20-F ☒   Form 40-F ☐       EXHIBIT INDEX   Exhibit Number Description 99.1  20 September 2024 – “Transaction in Own Shares”         99.1           Haleon plc:   Transaction in own shares   20 September 2024:   Haleon plc (the "Company" or "Haleon") today announces   the purchase of the following number of ordinary shares of £0.01 each in the Company (the "Shares") for cancellation   under its share buyback programme announced on 1 August 2024   (the "Buyback Programme").   Date of purchase: 20 September 2024 Number of Shares purchased: 668,200 Highest price paid per Share (p): 391.3000 Lowest price paid per Share (p): 386.5000 Volume weighted average price paid per Share (p): 389.0900   Following the settlement of the above, the Company's registered share capital consists of 9,115,658,323 ordinary shares. This figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.   In accordance with Article 5s(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:   http://www.rns-pdf.londonstockexchange.com/rns/1275F_1-2024-9-20.pdf   This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.   This announcement and individual trade breakdown will also be available on the Company's website at:   www.haleon.com/investors .   Enquiries     Investors Media   Sonya Ghobrial   +44 7392 784784 Zoë   Bird +44 7736 746167 Rakesh Patel      +44 7552 484646 Gemma Thomas +44 7985 175048 Emma White +44 7823 523562     Email:   investor-relations@haleon.com Email:  corporate.media@haleon.com   About Haleon Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.   For more information, please visit   www.haleon.com .                  SIGNATURE       Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.       HALEON PLC (Registrant)   Date: September 20, 2024 By: /s/ Amanda Mellor     Name: Amanda Mellor     Title: Company Secretary